The Chinese drug administration accepted the application of Beijing Centergate Technologies Holding's (SHE:000931) unit, Beijing Huasu Pharmaceutical, for the consistency evaluation of tramadol hydrochloride tablets, according to a Shenzhen Stock Exchange disclosure on Monday.
The drug is clinically used to treat pain in adults whose pain is severe enough to require the use of opioid analgesics and for whom alternative therapies are insufficient.
Shares of the Chinese biomedicine and personal care products producer jumped over 4% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments